CAPITAL STOCK (Details Narrative) - USD ($) |
1 Months Ended | 5 Months Ended | 6 Months Ended | 8 Months Ended | 12 Months Ended | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 10, 2026 |
Jan. 14, 2026 |
Dec. 01, 2025 |
May 08, 2025 |
Jul. 08, 2024 |
Apr. 01, 2024 |
Jun. 06, 2023 |
Jan. 23, 2026 |
Dec. 23, 2025 |
Jun. 25, 2025 |
May 23, 2025 |
Jan. 31, 2024 |
Sep. 30, 2021 |
Aug. 31, 2024 |
Apr. 30, 2026 |
Apr. 30, 2025 |
Apr. 30, 2024 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Oct. 31, 2025 |
Oct. 31, 2024 |
Feb. 02, 2025 |
Aug. 17, 2022 |
|
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Preferred stock, shares authorized | 10,000,000 | |||||||||||||||||||||||
| Preferred stock, par value | $ 0.001 | |||||||||||||||||||||||
| Number of units sold | 8.2 | |||||||||||||||||||||||
| Aggregate purchase price | $ 2,050,000 | |||||||||||||||||||||||
| Shares description | Each Unit consists of (i) 62,500 shares of common stock and (ii) warrants to purchase 62,500 shares of common stock of the Company at an exercise price of $4.00 until November 30, 2030. The warrants may be exercised on a cashless basis. In connection with the sale of the Units, the Company issued 512,500 shares of common stock and 512,500 warrants to purchase shares of common stock. | |||||||||||||||||||||||
| Legal fees payable | $ 20,000 | |||||||||||||||||||||||
| Stock issued in exchange of legal fees payable, shares | 20,000 | |||||||||||||||||||||||
| Stock issued in exchange of legal fees payable | $ 20,000 | |||||||||||||||||||||||
| Monthly advance | $ 221,000 | |||||||||||||||||||||||
| Stock-based compensation expense | $ 4,930,000 | $ 4,693,000 | 3,853,000 | |||||||||||||||||||||
| Fair value of the shares as of the date of grant | $ 1,986,000 | $ 473,000 | $ 331,000 | |||||||||||||||||||||
| Non-vested shares granted | 792,500 | 180,000 | 185,000 | |||||||||||||||||||||
| Option vested | 103,333 | 105,000 | ||||||||||||||||||||||
| BioLumina, LLC [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Number of restricted shares acquired | 30,000 | |||||||||||||||||||||||
| Value of restricted shares acquired | $ 58,000 | |||||||||||||||||||||||
| Restricted Stock Awards [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Stock-based compensation expense | $ 104,000 | |||||||||||||||||||||||
| Grant of unvested restricted common stock | 40,000 | |||||||||||||||||||||||
| Fair value of the shares as of the date of grant | 104,000 | |||||||||||||||||||||||
| Unvested stock grants [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Stock-based compensation expense | $ 1,119,000 | $ 233,000 | $ 74,000 | |||||||||||||||||||||
| Unvested shares [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Non-vested shares granted | 962,000 | |||||||||||||||||||||||
| Shares issued | 525,000 | |||||||||||||||||||||||
| Twenty individuals [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Stock-based compensation expense | $ 34,000 | $ 82,000 | 57,000 | |||||||||||||||||||||
| Value of shares issued | $ 271,000 | |||||||||||||||||||||||
| Twenty individuals [Member] | Minimum [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Share Price | $ 1.04 | |||||||||||||||||||||||
| Twenty individuals [Member] | Maximum [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Share Price | $ 2.75 | |||||||||||||||||||||||
| Consultant [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Shares issued | 182,500 | |||||||||||||||||||||||
| Stock-based compensation expense | $ 34,000 | $ 143,000 | $ 143,000 | $ 72,000 | ||||||||||||||||||||
| Option vested | 20,833 | 50,000 | 50,000 | |||||||||||||||||||||
| Consultant [Member] | Consulting Agreement [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Stock-based compensation expense | $ 21,000 | |||||||||||||||||||||||
| Share Price | $ 2.05 | |||||||||||||||||||||||
| Number of shares awarded | 10,000 | |||||||||||||||||||||||
| Consultant [Member] | Minimum [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Share Price | $ 1.66 | |||||||||||||||||||||||
| Consultant [Member] | Maximum [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Share Price | $ 2.45 | |||||||||||||||||||||||
| 2021 Plan [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Maximum aggregate number of shares | 7,500,000 | 2,500,000 | 1,250,000 | |||||||||||||||||||||
| Number of shares, outstanding | 5,962,395 | 1,595,482 | ||||||||||||||||||||||
| Future issuance | 1,379,524 | 1,243,647 | ||||||||||||||||||||||
| Sales distribution agreement [Member] | Salesco [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Monthly advance | $ 15,000 | |||||||||||||||||||||||
| Shares granted | 30,000 | 300,000 | ||||||||||||||||||||||
| Vesting period | 2 years | 2 years | ||||||||||||||||||||||
| Cumulative sales from customers | $ 30,000 | |||||||||||||||||||||||
| Stock-based compensation expense | $ 60,000 | $ 8,000 | $ 18,000 | |||||||||||||||||||||
| Description incentive plan | Company’s Board of Directors (“Board”) awarded 125,000 and 62,500 shares of the Company’s common stock to Jerry Glauser and Leathem Stearn or their nominees, respectively (“Stock Grants”), both members of the Board, valued at $2.00 per share, the closing price of the common stock of the Company on the grant date. The Stock Grants vest in full as of the date of the grant. The Company recorded a total of $375,000 of stock-based compensation expense during the year ended October 31, 2024, in connection with the Stock Grants. | |||||||||||||||||||||||
| 2021 Incentive Stock Plan [Member] | Employee [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Stock-based compensation expense | $ 66,000 | $ 50,000 | ||||||||||||||||||||||
| Share Price | $ 2.66 | |||||||||||||||||||||||
| Number of shares awarded | 25,000 | |||||||||||||||||||||||
| 2021 Incentive Stock Plan [Member] | Dr. Kisiday [Member] | Employment Agreement [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Non-vested shares granted | 50,000 | |||||||||||||||||||||||
| 2021 Plan [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Stock-based compensation expense | $ 1,395,000 | $ 799,000 | ||||||||||||||||||||||
| Share Price | $ 2.66 | |||||||||||||||||||||||
| Number of shares awarded | 525,000 | |||||||||||||||||||||||
| 2021 Plan [Member] | Greyt Ventures LLC [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Number of shares awarded | 175,000 | |||||||||||||||||||||||
| 2021 Plan [Member] | Dr. Kisiday [Member] | Employment Agreement [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Stock-based compensation expense | $ 137,000 | |||||||||||||||||||||||
| Share Price | $ 2.74 | |||||||||||||||||||||||
| Non-vested shares granted | 50,000 | |||||||||||||||||||||||
| Forfeited in period | 50,000 | |||||||||||||||||||||||
| Investor [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Shares issued | 250,000 | |||||||||||||||||||||||
| Warrant to purchase | 83,333 | |||||||||||||||||||||||
| Subscription agreement description | ZEO entered into a subscription agreement (“Subscription Agreement”) with a single accredited investor (the “Investor”) pursuant to which the Investor agreed to purchase 250,000 shares of our common stock (the “Shares”) in a private transaction for an aggregate purchase price of $1,000,000 (the “Purchase Price”). The Shares were to be issued and sold and the Purchase Price paid in ten (10) equal monthly installments commencing on August 1, 2025 and ending on May 1, 2026. As of October 31, 2025, 75,000 shares have been sold for an aggregate of $300,000 in accordance with the Subscription Agreement. On November 1, 2025, an additional 25,000 shares were sold for $100,000 in accordance with the Subscription Agreement. On February 10, 2026, the Subscription Agreement was amended whereby the total number of Shares to be purchased under the Subscription Agreement was reduced to 100,000 Shares and no further shares are issuable. As of June 30, 2026, a total of 100,000 shares have been sold for an aggregate amount of $400,000 pursuant to the Subscription Agreement. | |||||||||||||||||||||||
| Fifteen Investors [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Shares issued | 512,500 | |||||||||||||||||||||||
| Number of units sold | 8.2 | |||||||||||||||||||||||
| Shares description | Each Unit consists of (i) 62,500 shares of common stock and (ii) warrants to purchase 62,500 shares of common stock of the Company at an exercise price of $4.00 until November 30, 2030. The warrants may be exercised on a cashless basis. | |||||||||||||||||||||||
| Number of warrants purchased | 512,500 | |||||||||||||||||||||||
| Eight Investors [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Aggregate purchase price | $ 2,050,000 | |||||||||||||||||||||||
| Consultant [Member] | Consulting Agreement [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Stock-based compensation expense | $ 1,428,000 | |||||||||||||||||||||||
| Fair value of the shares as of the date of grant | $ 1,428,000 | |||||||||||||||||||||||
| Grant of unvested restricted common stock description | In connection with the Consultant Agreement, the Company granted the Consultant 100,000 shares of common stock (“Shares”) and warrants to purchase an additional 500,000 shares of common stock (the “Warrants”). 50,000 of the Shares with a fair value of $143,000 vested upon execution of the Consulting Agreement and the remaining 50% with a fair value of $143,000 will vest on the six-month anniversary of the Consulting Agreement. During the periods ended June 30, 2026 and the year ended October 31, 2025, the Company amortized $143,000 and $143,000, respectively, of expenses related to the fair value of the shares. The Warrants vest in five equal tranches of 100,000 shares, at various exercise prices ranging between $3.50 - $10.00 per share, and are exercisable on the terms provided in the Consulting Agreement. Once vested, the Warrants are exercisable for a period of ninety (90) days from the date they become exercisable. The Company valued the warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate 4.00%, (2) term of 3 years, (3) expected stock volatility of 143%, and (4) expected dividend rate of 0%. | |||||||||||||||||||||||
| Second Consultant [Member] | Consulting Agreement [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Stock-based compensation expense | $ 82,000 | |||||||||||||||||||||||
| Fair value of the shares as of the date of grant | $ 82,000 | |||||||||||||||||||||||
| Grant of unvested restricted common stock description | in connection with an agreement with a second consultant (“Second Consultant”), the Company agreed to grant the Second Consultant 40,000 shares of the Company’s common stock which shall vest quarterly over a 2-year period commencing on the date that sales obtained by the Company from customers introduced by Second Consultant exceed $400,000 (“Milestone”) and provided that the Milestone is achieved by December 31, 2025. Upon termination of the agreement for any reason, any unvested stock shall be forfeited. In addition, the Second Consultant will be entitled to receive commissions on sales of the Company’s products to customers introduced by the Second Consultant in the form of cash and common stock of the Company based on sales milestones. The agreement may be terminated at any time by either party upon 30 days written notice. | |||||||||||||||||||||||
| Chief Executive Officer [Member] | 2021 Plan [Member] | Ian Bothwell [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Number of shares awarded | 175,000 | |||||||||||||||||||||||
| Chief Medical Officer [Member] | 2021 Plan [Member] | Dr. George Shapiro [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Number of shares awarded | 175,000 | |||||||||||||||||||||||
| Series C Non-Convertible Preferred Stock [Member] | ||||||||||||||||||||||||
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Preferred stock, shares authorized | 100 | |||||||||||||||||||||||
| Preferred stock, par value | $ 0.001 | |||||||||||||||||||||||